Immunogenic compositions to treat and prevent microbial infections
The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.
1. An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises one or more epitopes of a Mycobacterium and one or more epitopes of an influenza virus wherein the plurality is contained in a contiguous peptide sequence, and the immunogenic peptide contains one or more sequences selected from the group consisting of SEQ ID NOs. 3-8, 15, 20, 22-24, 29, 37, 46-48, and 61.
2. The peptide of claim 1 , wherein the one or more influenza virus epitopes are selected from the group consisting of epitopes of an HA protein, an NA protein, an M1 protein, an M2 protein, an M2e protein of the influenza virus, and fragments, derivatives, and modifications thereof.
3. The peptide of claim 1 , wherein the one or more epitopes of a Mycobacterium are selected from the group consisting of epitopes of a peptidoglycan, a mycolic acid, a heat shock protein, a cell surface protein, an internal antigen, a lipoarabinomannan, and fragments, derivatives, and modifications thereof.
4. The peptide of claim 1 , which comprises at least one T cell stimulating epitope.
5. The peptide of claim 4 , wherein the T cell stimulating epitope is an epitope of tetanus toxin, tetanus toxin heavy chain proteins, diphtheria toxoid, CRM, recombinant CRM, tetanus toxoid, Pseudomonas exoprotein A, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid, Clostridium perfringens toxoid, Escherichia coli heat-labile toxin B subunit, Neisseria meningitidis outer membrane complex, Hemophilus influenzae protein D, Flagellin Fli C, Horseshoe crab Haemocyanin, and/or a fragment, derivative, or modification thereof.
6. The peptide of claim 4 , wherein the T cell stimulating epitope is at the N-terminus of the peptide.
7. The peptide of claim 4 , wherein the T cell stimulating epitope is at the C-terminus of the peptide.
8. The peptide of claim 4 , wherein the T cell stimulating epitope is at an internal region of the peptide.
9. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable diluent, excipient, or carrier.
10. The composition of claim 9 , further comprising an adjuvant.
11. The composition of claim 10 , wherein the adjuvant is selected from the group consisting of Freund's, a liposome, saponin, lipid A, squalene, and derivatives and combinations thereof.
12. A vaccine comprising the peptide of claim 1 .
13. An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises one or more epitopes of peptidoglycan of a Mycobacterium and one or more epitopes of a neuraminidase protein of an influenza virus wherein the plurality is contained in a contiguous peptide sequence, and the immunogenic peptide contains one or more sequences selected from the group consisting of SEQ ID NOs. 3, 4, 15, 37, 46, 47, and 48.
14. An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises one or more epitopes of a heat shock protein of a Mycobacterium and one or more epitopes of a matrix protein of an influenza virus wherein the plurality is contained in a contiguous peptide sequence, and the immunogenic peptide contains one or more sequences selected from the group consisting of SEQ ID NOs. 20, 24, 29, 37, 46, and 61.
15. An immunogenic peptide containing as a contiguous sequence a sequence selected from the group consisting of SEQ ID NOs. 113 and 114.
16. A composition containing the peptide of claim 15 plus a pharmaceutically acceptable diluent, excipient, or carrier.
17. The composition of claim 15 , further comprising an adjuvant.
18. The composition of claim 17 , wherein the adjuvant is selected from the group consisting of Freund's, a liposome, saponin, lipid A, squalene, and derivatives and combinations thereof.